Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysozyme g-like protein 1 (LYG1)
- Target
- LYG1
- Molecular classification
- Enzyme (lysozyme-family, glycoside hydrolase), Secreted protein (cytokine-like properties)
01
Overview
Lysozyme g-like protein 1 (LYG1) is a member of the lysozyme superfamily, characterized as a secreted protein with structural similarity to goose-type lysozymes but possessing minimal classical bacteriolytic activity. LYG1 is expressed broadly but is most abundant in the kidney. Functionally, LYG1 operates as an immunomodulator: it promotes the activation, proliferation, and IFNγ production of CD4^+ T cells—thereby enhancing antitumor immune responses. Its antitumor effects in mouse models are dependent on both CD4^+ and CD8^+ T lymphocytes, acting largely through immune modulation rather than direct cytotoxic/bacteriolytic activity. In addition, LYG1 is predicted to play a role in defense against Gram-positive bacteria, though its catalytic lysozyme activity appears limited in humans. No specific clinically approved drugs or biomarkers are directly linked to LYG1 as a therapeutic target yet.
- Other names
- Lysozyme g1Lysozyme G-like 1LYGA1SALW1939UNQ1939/PRO4422Lysozyme g-like protein 1
02
Biological functions
Immune response (involved in defense against Gram-positive bacteria)Immunoregulation (promotes CD4^+ T cell activation, proliferation, and IFNγ production)Antitumor activity (stimulates tumor-infiltrating lymphocyte function and inhibits tumor growth)
03
Disease associations
Cancer (antitumor immunity, tumor progression modulation)Infection (predicted role in defense against Gram-positive bacteria)
04
Safety considerations
No notable safety issues reported in animal models; knockout shows immune effects without reported toxicity
Beyond the preview
Go deeper on Lysozyme g-like protein 1 (LYG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lysozyme g-like protein 1 (LYG1).